Frontiers in Immunology (Feb 2022)

Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects

  • Chen-xi Zhang,
  • Ye Tu,
  • Xiao-chen Sun,
  • Da-gui Chen,
  • Wan-nian Zhang,
  • Wan-nian Zhang,
  • Chun-lin Zhuang,
  • Chun-lin Zhuang,
  • Zhi-bin Wang,
  • Zhi-bin Wang,
  • Li Su

DOI
https://doi.org/10.3389/fimmu.2022.856327
Journal volume & issue
Vol. 13

Abstract

Read online

Coronavirus Disease 2019 (COVID-19) infected by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a public health emergency of international concerns. Cytokine storm syndrome (CSS) is a critical clinical symptom of severe COVID-19 patients, and the macrophage is recognized as the direct host cell of SARS-CoV-2 and potential drivers of CSS. In the present study, peramivir was identified to reduce TNF-α by partly intervention of NF-κB activity in LPS-induced macrophage model. In vivo, peramivir reduced the multi-cytokines in serum and bronchoalveolar lavage fluid (BALF), alleviated the acute lung injury and prolonged the survival time in mice. In human peripheral blood mononuclear cells (hPBMCs), peramivir could also inhibit the release of TNF-α. Collectively, we proposed that peramivir might be a candidate for the treatment of COVID-19 and other infections related CSS.

Keywords